SI1771208T1 - Uporaba tioflavinskih radioaktivnih derivatov v amiloidnih posnetkih za ocenjevanje proti amiloidnih terapij - Google Patents

Uporaba tioflavinskih radioaktivnih derivatov v amiloidnih posnetkih za ocenjevanje proti amiloidnih terapij

Info

Publication number
SI1771208T1
SI1771208T1 SI200531765T SI200531765T SI1771208T1 SI 1771208 T1 SI1771208 T1 SI 1771208T1 SI 200531765 T SI200531765 T SI 200531765T SI 200531765 T SI200531765 T SI 200531765T SI 1771208 T1 SI1771208 T1 SI 1771208T1
Authority
SI
Slovenia
Prior art keywords
amyloid
thioflavin
therapies
imaging
radiolabeled derivatives
Prior art date
Application number
SI200531765T
Other languages
English (en)
Slovenian (sl)
Inventor
William E. Klunk
Chester A. Mathis Jr
Original Assignee
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Publication of SI1771208T1 publication Critical patent/SI1771208T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
SI200531765T 2004-07-02 2005-07-01 Uporaba tioflavinskih radioaktivnih derivatov v amiloidnih posnetkih za ocenjevanje proti amiloidnih terapij SI1771208T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58448704P 2004-07-02 2004-07-02
PCT/US2005/023617 WO2006014381A2 (en) 2004-07-02 2005-07-01 Use of thioflavin radiolabeled derivatives in amyloid imaging gor assessing anti-amyloid therapies
EP05787557.7A EP1771208B1 (en) 2004-07-02 2005-07-01 Use of thioflavin radiolabeled derivatives in amyloid imaging for assessing anti-amyloid therapies

Publications (1)

Publication Number Publication Date
SI1771208T1 true SI1771208T1 (sl) 2013-10-30

Family

ID=35504952

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531765T SI1771208T1 (sl) 2004-07-02 2005-07-01 Uporaba tioflavinskih radioaktivnih derivatov v amiloidnih posnetkih za ocenjevanje proti amiloidnih terapij

Country Status (16)

Country Link
US (4) US8147798B2 (pt-PT)
EP (1) EP1771208B1 (pt-PT)
JP (1) JP2008505115A (pt-PT)
CN (2) CN101137397A (pt-PT)
AU (1) AU2005270026A1 (pt-PT)
BR (1) BRPI0512893B8 (pt-PT)
CA (2) CA2830939C (pt-PT)
CY (1) CY1114644T1 (pt-PT)
DK (1) DK1771208T3 (pt-PT)
ES (1) ES2427963T3 (pt-PT)
NO (1) NO339187B1 (pt-PT)
PL (1) PL1771208T3 (pt-PT)
PT (1) PT1771208E (pt-PT)
RU (1) RU2007104107A (pt-PT)
SI (1) SI1771208T1 (pt-PT)
WO (1) WO2006014381A2 (pt-PT)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
PL215711B1 (pl) * 2000-08-24 2014-01-31 Univ Pittsburgh Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
WO2007035405A2 (en) * 2005-09-16 2007-03-29 University Of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
PL2182983T3 (pl) * 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
WO2009027452A2 (en) * 2007-08-30 2009-03-05 Ge Healthcare Limited Radiopharmaceutical composition
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5603855B2 (ja) 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
RU2518892C2 (ru) * 2008-09-23 2014-06-10 Виста Лабораториз Лтд. Лиганды для агрегированных молекул тау-белка
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010053218A1 (en) * 2008-11-06 2010-05-14 Snu R&Db Foundation Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same
JP2013521233A (ja) * 2010-02-25 2013-06-10 ヤンセン アルツハイマー イミュノセラピー Ａβを標的とする免疫療法のＰＥＴモニタリング
WO2014004664A2 (en) * 2012-06-27 2014-01-03 Mayo Foundation For Medical Education And Research Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
US9422286B2 (en) 2014-01-27 2016-08-23 Washington University Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease
AU2016308189B2 (en) * 2015-08-18 2021-03-11 The Regents Of The University Of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092003A1 (en) * 1999-12-29 2003-05-15 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of Alzheimer's disease
PL215711B1 (pl) * 2000-08-24 2014-01-31 Univ Pittsburgh Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
DE60217090T2 (de) * 2001-04-23 2007-07-12 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
JP2005523903A (ja) 2002-02-13 2005-08-11 アメルシャム・パブリック・リミテッド・カンパニー アミロイド斑の生体内撮像用のベンゾチアゾール誘導体
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
GB0307855D0 (en) 2003-04-04 2003-05-14 Novartis Ag Organic compounds
BRPI0512932A (pt) * 2004-07-02 2008-04-15 Univ Pittsburgh compostos e métodos de identificação e de diagnóstico de paciente como prodrÈmico para doença associada com a deposição amilóide

Also Published As

Publication number Publication date
US20130045164A1 (en) 2013-02-21
NO339187B1 (no) 2016-11-14
CN102973954A (zh) 2013-03-20
US20140105820A1 (en) 2014-04-17
WO2006014381A2 (en) 2006-02-09
ES2427963T3 (es) 2013-11-05
CA2587248C (en) 2014-01-07
EP1771208A2 (en) 2007-04-11
US8343457B2 (en) 2013-01-01
BRPI0512893A (pt) 2008-04-15
RU2007104107A (ru) 2008-08-10
US8147798B2 (en) 2012-04-03
CA2830939C (en) 2017-02-28
NO20070593L (no) 2007-03-27
WO2006014381A9 (en) 2006-04-13
PT1771208E (pt) 2013-09-24
WO2006014381A3 (en) 2007-01-18
BRPI0512893B1 (pt) 2019-12-24
CA2587248A1 (en) 2006-02-09
DK1771208T3 (da) 2013-09-02
CA2830939A1 (en) 2006-02-09
CY1114644T1 (el) 2016-10-05
PL1771208T3 (pl) 2013-11-29
AU2005270026A1 (en) 2006-02-09
US20080219931A1 (en) 2008-09-11
EP1771208B1 (en) 2013-06-19
BRPI0512893B8 (pt) 2021-07-27
US8580229B2 (en) 2013-11-12
US20120177572A1 (en) 2012-07-12
JP2008505115A (ja) 2008-02-21
CN101137397A (zh) 2008-03-05

Similar Documents

Publication Publication Date Title
SI1771208T1 (sl) Uporaba tioflavinskih radioaktivnih derivatov v amiloidnih posnetkih za ocenjevanje proti amiloidnih terapij
HUS1500014I1 (hu) Sztilbén-származékok és alkalmazásuk amiloid plakkok megjelenítésére
EP2023919A4 (en) COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
EP1886112A4 (en) METHOD FOR MEASURING THE METABOLISM OF NATURALLY DERIVED BIOMOLECULES IN VIVO
EP1933884A4 (en) PICTURES AND METHOD FOR THEIR USE
EP1718194A4 (en) MRI PROBE FOR THE PICTORIAL PROSTATE PRESENTATION
EP1848466A4 (en) MRI CONTRAST AGENTS FOR DIAGNOSIS AND PROGNOSIS OF TUMORS
CY2013024I2 (el) Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
IL195044A0 (en) Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
HK1114171A1 (en) Copeptin-based diagnostic kit for disorders
ZA201002926B (en) Use of anti-amyloid beta antibody in ocular disease
IL195271A0 (en) Composition for diagnosing amyloid-related disease
IL199201A (en) Acetylene history and their use for linking and imaging of amyloid layers
EP2117607A4 (en) IMAGING AGENTS AND METHODS OF USE
EP1787116A4 (en) METHOD FOR ASSESSING THE RISK OF DEVELOPING A CARDIOVASCULAR DISEASE
GB0513812D0 (en) Compounds for imaging and therapy
EP2223121A4 (en) METHOD AND KIT FOR USE IN THE DIFFERENTIATION OF IBD AND IBS AND IN COMPLEMENTARY DISTINCTION BETWEEN DIFFERENT TYPES OF IBD DISEASES
HK1084723A1 (en) Probe for three-dimensional measurements
EP1868504A4 (en) DENTAL COMPUTER TOMOGRAPHIC PRESENTATION
EP2144916A4 (en) PHENYLNAPHTHALENE DERIVATIVES AND PHENYLQUINOLINES AND THEIR USE FOR THE BINDING AND FORMATION OF AMYLOID PLATE IMAGES
IL182404A0 (en) Mutated amyloid protein
HK1144252A1 (en) Methods for drug screening using non-invasive in vivo imaging
EP1968442A4 (en) IN SITU HYPERPOLARIZATION OF IMAGING AGENTS
EP1870710A4 (en) BIOMARKERS FOR DIAGNOSIS OF DISEASE AND USE THEREOF
ZA201102689B (en) Piperazine derivatives for binding and imaging amyloid plaques and their use